In the MPTP mouse model, the activation of the NLRP3 inflammasome in MG was shown to play a key role in the loss of dopaminergic neurons and the impairment of motor function; the application of an IL-1 receptor blocker significantly reduced the motor symptoms of the mouse model of PD (Lee et al., 2019). The gene discussed is NLRP3; the disease is myasthenia gravis.